{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:07:12Z","timestamp":1793110032330,"version":"4.5.0"},"reference-count":96,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) are global diseases of increasing prevalence and are frequent co-diagnoses. The two conditions share common risk factors and CKD contributes to HFpEF development by a variety of mechanisms including systemic inflammation and myocardial fibrosis. HFpEF patients with CKD are generally older and have more advanced disease. CKD is a poor prognostic indicator in HFpEF, while the impact of HFpEF on CKD prognosis is not sufficiently investigated. Acute kidney injury (AKI) is common during admission with acute decompensated HFpEF, but short and long-term outcomes are not clear. Pharmacological treatment options for HFpEF are currently minimal, and even more so limited in the presence of CKD with hyperkalaemia being one of the main concerns encountered in clinical practice. Recent data on the role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the management of HFpEF are encouraging, especially in light of the abundance of evidence supporting improved renal outcomes. Herein, we review the pathophysiological links between HFpEF and CKD, the clinical picture of dual diagnosis, as well as concerns with regards to renal impairment in the context of HFpEF management.<\/jats:p>","DOI":"10.31083\/j.rcm2302069","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T01:40:01Z","timestamp":1645753201000},"source":"Crossref","is-referenced-by-count":26,"title":["Interrelation between heart failure with preserved ejection fraction and renal impairment"],"prefix":"10.31083","volume":"23","author":[{"given":"Jennifer Ruth","family":"Joslin","sequence":"first","affiliation":[{"name":"King\u2019s Kidney Care, King\u2019s College Hospital, SE5 9RS London, UK"},{"name":"Centre for Nephrology, Urology and Transplantation, King\u2019s College London, SE5 9NU London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Lioudaki","sequence":"first","affiliation":[{"name":"King\u2019s Kidney Care, King\u2019s College Hospital, SE5 9RS London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Androulakis","sequence":"first","affiliation":[{"name":"Heart Imaging Centre, Royal Brompton and Harefield Hospitals, SW3 6NP London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2017; 14: 591\u2013602.","DOI":"10.1038\/nrcardio.2017.65"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019; 40: 3297\u20133317.","DOI":"10.1093\/eurheartj\/ehz641"},{"key":"ref3","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395: 709\u2013733."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Paulus WJ, Zile MR. From Systemic Inflammation to Myocardial Fibrosis. Circulation Research. 2021; 128: 1451\u20131467.","DOI":"10.1161\/CIRCRESAHA.121.318159"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Dini FL, Demmer RT, Simioniuc A, Morrone D, Donati F, Guarini G, et al. Right ventricular dysfunction is associated with chronic kidney disease and predicts survival in patients with chronic systolic heart failure. European Journal of Heart Failure. 2012; 14: 287\u2013294.","DOI":"10.1093\/eurjhf\/hfr176"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure. 2016; 18: 103\u2013112.","DOI":"10.1002\/ejhf.445"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Patel RB, Mehta R, Redfield MM, Borlaug BA, Hernandez AF, Shah SJ, et al. Renal Dysfunction in Heart Failure with Preserved Ejection Fraction: insights from the RELAX Trial. Journal of Cardiac Failure. 2020; 26: 233\u2013242.","DOI":"10.1016\/j.cardfail.2020.01.003"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015; 131: 269\u2013279.","DOI":"10.1161\/CIRCULATIONAHA.114.010637"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Zelnick LR, Katz R, Young BA, Correa A, Kestenbaum BR, de Boer IH, et al. Echocardiographic Measures and Estimated GFR Decline among African Americans: the Jackson Heart Study. American Journal of Kidney Diseases. 2017; 70: 199\u2013206.","DOI":"10.1053\/j.ajkd.2016.11.022"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Ravera M, Noberasco G, Signori A, Re M, Filippi A, Cannav\u00f2 R, et al. Left-ventricular hypertrophy and renal outcome in hypertensive patients in primary-care. American Journal of Hypertension. 2013; 26: 700\u2013707.","DOI":"10.1093\/ajh\/hps100"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011; 124: 2491\u20132501.","DOI":"10.1161\/CIRCULATIONAHA.110.011031"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling\/dysfunction. Journal of the American College of Cardiology. 2007; 49: 198\u2013207.","DOI":"10.1016\/j.jacc.2006.08.050"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Lam CSP, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007; 115: 1982\u20131990.","DOI":"10.1161\/CIRCULATIONAHA.106.659763"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Hsiao S, Chiou K. Renal function decline predicted by left atrial expansion index in non-diabetic cohort with preserved systolic heart function. European Heart Journal Cardiovascular Imaging. 2017; 18: 521\u2013528.","DOI":"10.1093\/ehjci\/jew224"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gan GCH, Bhat A, Kadappu KK, Fernandez F, Gu KH, Chen HHL, et al. Usefulness of Left Atrial Strain to Predict End Stage Renal Failure in Patients with Chronic Kidney Disease. The American Journal of Cardiology. 2021; 151: 105\u2013113.","DOI":"10.1016\/j.amjcard.2021.03.056"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Guazzi M, Ghio S, Adir Y. Pulmonary Hypertension in HFpEF and HFrEF. Journal of the American College of Cardiology. 2020; 76: 1102\u20131111.","DOI":"10.1016\/j.jacc.2020.06.069"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Vanderpool RR, Saul M, Nouraie M, Gladwin MT, Simon MA. Association between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure with Preserved Ejection Fraction. JAMA Cardiology. 2018; 3: 298\u2013306.","DOI":"10.1001\/jamacardio.2018.0128"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Issa N, Krowka MJ, Griffin MD, Hickson LJ, Stegall MD, Cosio FG. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation. 2008; 86: 1384\u20131388.","DOI":"10.1097\/TP.0b013e318188d640"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Zlotnick DM, Axelrod DA, Chobanian MC, Friedman S, Brown J, Catherwood E, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrology, Dialysis, Transplantation. 2010; 25: 3090\u20133096.","DOI":"10.1093\/ndt\/gfq141"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Agrawal A, Naranjo M, Kanjanahattakij N, Rangaswami J, Gupta S. Cardiorenal syndrome in heart failure with preserved ejection fraction\u2014an under-recognized clinical entity. Heart Failure Reviews. 2019; 24: 421\u2013437.","DOI":"10.1007\/s10741-018-09768-9"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Klein DA, Katz DH, Beussink-Nelson L, Sanchez CL, Strzelczyk TA, Shah SJ. Association of Chronic Kidney Disease with Chronotropic Incompetence in Heart Failure with Preserved Ejection Fraction. The American Journal of Cardiology. 2015; 116: 1093\u20131100.","DOI":"10.1016\/j.amjcard.2015.06.038"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Lo KB, Mezue K, Ram P, Goyal A, Shah M, Krishnamoorthy P, et al. Echocardiographic and Hemodynamic Parameters Associated with Diminishing Renal Filtration among Patients with Heart Failure with Preserved Ejection Fraction. Cardiorenal Medicine. 2019; 9: 83\u201391.","DOI":"10.1159\/000494089"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. European Heart Journal. 2013; 34: 1424\u20131431.","DOI":"10.1093\/eurheartj\/eht066"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Rieger AC, Bagno LL, Salerno A, Florea V, Rodriguez J, Rosado M, et al. Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. Proceedings of the National Academy of Sciences of the United States of America. 2021; 118: e2019835118 .","DOI":"10.1101\/2020.05.30.111476"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Hickson LJ, Negrotto SM, Onuigbo M, Scott CG, Rule AD, Norby SM, et al. Echocardiography Criteria for Structural Heart Disease in Patients with End-Stage Renal Disease Initiating Hemodialysis. Journal of the American College of Cardiology. 2016; 67: 1173\u20131182.","DOI":"10.1016\/j.jacc.2015.12.052"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013; 62: 263\u2013271.","DOI":"10.1016\/j.jacc.2013.02.092"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Mihai S, Codrici E, Popescu ID, Enciu A, Albulescu L, Necula LG, et al. Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. Journal of Immunology Research. 2018; 2018: 2180373.","DOI":"10.1155\/2018\/2180373"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Upadhya B, Amjad A, Stacey RB. Optimizing the Management of Obese HFpEF Phenotype: can we Mind both the Heart and the Kidney? Journal of Cardiac Failure. 2020; 26: 108\u2013111.","DOI":"10.1016\/j.cardfail.2019.11.018"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Faul C, Amaral AP, Oskouei B, Hu M, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. The Journal of Clinical Investigation. 2011; 121: 4393\u20134408.","DOI":"10.1172\/JCI46122"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney International. 2004; 65: 1568\u20131576.","DOI":"10.1111\/j.1523-1755.2004.00552.x"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Nickel NP, O\u2019Leary JM, Brittain EL, Fessel JP, Zamanian RT, West JD, et al. Kidney dysfunction in patients with pulmonary arterial hypertension. Pulmonary Circulation. 2017; 7: 38\u201354.","DOI":"10.1086\/690018"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Chapter 1: Definition and classification of CKD. Kidney International Supplement . 2013; 3: 19\u201362.","DOI":"10.1038\/kisup.2012.64"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Lejeune S, Roy C, Slimani A, Pasquet A, Vancraeynest D, Beauloye C, et al. Heart failure with preserved ejection fraction in Belgium: characteristics and outcome of a real-life cohort. Acta Cardiologica. 2020; 76: 697\u2013706.","DOI":"10.1080\/00015385.2020.1770460"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Tromp J, Teng T, Tay WT, Hung CL, Narasimhan C, Shimizu W, et al. Heart failure with preserved ejection fraction in Asia. European Journal of Heart Failure. 2019; 21: 23\u201336.","DOI":"10.1002\/ejhf.1227"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2019; 381: 1609\u20131620.","DOI":"10.1056\/NEJMoa1908655"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. The Lancet. 2009; 374: 543\u2013550.","DOI":"10.1016\/S0140-6736(09)61378-7"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, et al. Efficacy and Safety of Spironolactone in Patients with HFpEF and Chronic Kidney Disease. JACC: Heart Failure. 2019; 7: 25\u201332.","DOI":"10.1016\/j.jchf.2018.10.017"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Antlanger M, Aschauer S, Kopecky C, Hecking M, Kovarik JJ, Werzowa J, et al. Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis. Kidney &Amp; Blood Pressure Research. 2017; 42: 165\u2013176.","DOI":"10.1159\/000473868"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Chisavu LA, Apostol A, Pop GN, Ivan V, Schiller O, Bob F, et al. Exploring the relation between mortality and left ventricular structure and function in stable hemodialysis treated patients, a longitudinal multicenter cohort study. Scientific Reports. 2021; 11: 12694.","DOI":"10.1038\/s41598-021-91431-9"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Zhong Y, Cai Y, Liu M, Bai W, Wang F, Tang H, et al. Left ventricular diastolic pressure gradient and outcome in advanced chronic kidney disease patients with preserved ejection fraction. The International Journal of Cardiovascular Imaging. 2021; 37: 2663\u20132673.","DOI":"10.1007\/s10554-021-02339-4"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Wang AY, Wang M, Lam CW, Chan IH, Lui S, Sanderson JE. Heart failure with preserved or reduced ejection fraction in patients treated with peritoneal dialysis. American Journal of Kidney Diseases. 2013; 61: 975\u2013983.","DOI":"10.1053\/j.ajkd.2012.12.030"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Mukherjee M, Sharma K, Madrazo JA, Tedford RJ, Russell SD, Hays AG. Right-Sided Cardiac Dysfunction in Heart Failure with Preserved Ejection Fraction and Worsening Renal Function. The American Journal of Cardiology. 2017; 120: 274\u2013278.","DOI":"10.1016\/j.amjcard.2017.04.019"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Claggett BL, Liu J, Desai AS, Pfeffer MA, Anand IS, et al. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure. 2021; 23: 776\u2013784.","DOI":"10.1002\/ejhf.2134"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Segar MW, Patel RB, Patel KV, Fudim M, DeVore AD, Martens P, et al. Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American Medical Association Cardiology. 2021; 6: 68\u201377.","DOI":"10.1001\/jamacardio.2020.5592"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Chirinos JA, Orlenko A, Zhao L, Basso MD, Cvijic ME, Li Z, et al. Multiple Plasma Biomarkers for Risk Stratification in Patients with Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology. 2020; 75: 1281\u20131295.","DOI":"10.1016\/j.jacc.2019.12.069"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Katz DH, Burns JA, Aguilar FG, Beussink L, Shah SJ. Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. JACC: Heart Failure. 2014; 2: 586\u2013596.","DOI":"10.1016\/j.jchf.2014.05.016"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Oeun B, Hikoso S, Nakatani D, Mizuno H, Suna S, Kitamura T, et al. Prognostic significance of dipstick proteinuria in heart failure with preserved ejection fraction: insight from the PURSUIT-HFpEF registry. BMJ Open. 2021; 11: e049371.","DOI":"10.1136\/bmjopen-2021-049371"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Kohno H, et al. Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study. European Journal of Heart Failure. 2012; 14: 367\u2013376.","DOI":"10.1093\/eurjhf\/hfs001"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Chen S, Huang J, Su H, Chiu Y, Chang J, Hwang S, et al. Prognostic Cardiovascular Markers in Chronic Kidney Disease. Kidney &Amp; Blood Pressure Research. 2018; 43: 1388\u20131407.","DOI":"10.1159\/000492953"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Gergei I, Kr\u00e4mer BK, Scharnagl H, Stojakovic T, M\u00e4rz W. Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction. Peptides. 2019; 111: 112\u2013117.","DOI":"10.1016\/j.peptides.2018.04.003"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Obokata M, Dean PG, Melenovsky V, Nath KA, Borlaug BA. Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. European Heart Journal. 2017; 38: 1913\u20131923.","DOI":"10.1093\/eurheartj\/ehx045"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Khan YH, Sarriff A, Adnan AS, Khan AH, Mallhi TH. Chronic Kidney Disease, Fluid Overload and Diuretics: A Complicated Triangle. PLoS One. 2016; 11: e0159335.","DOI":"10.1371\/journal.pone.0159335"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of Vasodilation in Heart Failure with Preserved or Reduced Ejection Fraction. Journal of the American College of Cardiology. 2012; 59: 442\u2013451.","DOI":"10.1016\/j.jacc.2011.09.062"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. The New England Journal of Medicine. 2008; 359: 2456\u20132467.","DOI":"10.1056\/NEJMoa0805450"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Damman K, Perez AC, Anand IS, Komajda M, McKelvie RS, Zile MR, et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology. 2014; 64: 1106\u20131113.","DOI":"10.1016\/j.jacc.2014.01.087"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362: 777\u2013781.","DOI":"10.1016\/S0140-6736(03)14285-7"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure. 2018; 20: 1230\u20131239.","DOI":"10.1002\/ejhf.1149"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. The New England Journal of Medicine. 2014; 370: 1383\u20131392.","DOI":"10.1056\/NEJMoa1313731"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal. 2016; 37: 455\u2013462.","DOI":"10.1093\/eurheartj\/ehv464"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015; 131: 34\u201342.","DOI":"10.1161\/CIRCULATIONAHA.114.013255"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Khan MS, Khan MS, Moustafa A, Anderson AS, Mehta R, Khan SS. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients with Heart Failure and Chronic Kidney Disease. The American Journal of Cardiology. 2020; 125: 643\u2013650.","DOI":"10.1016\/j.amjcard.2019.11.014"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O\u2019Meara E, et al. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure with Preserved Ejection Fraction. Circulation: Heart Failure. 2018; 11: e005288.","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Solomon SD, Vaduganathan M, L. Claggett B, Packer M, Zile M, Swedberg K, et al. SacubitrilValsartan across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020; 141: 352\u2013361.","DOI":"10.1161\/CIRCULATIONAHA.119.044586"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Gronda E, Vanoli E, Iacoviello M. The PARAGON-HF trial: the sacubitril\/valsartan in heart failure with preserved ejection fraction. European Heart Journal Supplements. 2020; 22: L77\u2013L81.","DOI":"10.1093\/eurheartj\/suaa140"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Jering KS, Zannad F, Claggett B, Mc Causland FR, Ferreira JP, Desai A, et al. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. JACC: Heart Failure. 2021; 9: 13\u201324.","DOI":"10.1016\/j.jchf.2020.08.014"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Fu S, Xu Z, Lin B, Chen J, Huang Q, Xu Y, et al. Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis. Frontiers in Medicine. 2021; 8: 657067.","DOI":"10.3389\/fmed.2021.657067"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Grossekettler L, Schmack B, Meyer K, Brockmann C, Wanninger R, Kreusser MM, et al. Peritoneal dialysis as therapeutic option in heart failure patients. European Society of Cardiology Heart Failure. 2019; 6: 271\u2013279.","DOI":"10.1002\/ehf2.12411"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Grossekettler L, Schmack B, Brockmann C, Wanninger R, Kreusser MM, Frankenstein L, et al. Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients. BMC Nephrology. 2020; 21: 179.","DOI":"10.1186\/s12882-020-01777-x"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Bart BA, Goldsmith SR, Lee KL, Givertz MM, O\u2019Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. The New England Journal of Medicine. 2012; 367: 2296\u20132304.","DOI":"10.1056\/NEJMoa1210357"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Savarese G, Xu H, Trevisan M, Dahlstr\u00f6m U, Rossignol P, Pitt B, et al. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction. JACC: Heart Failure. 2019; 7: 65\u201376.","DOI":"10.1016\/j.jchf.2018.10.003"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Shrestha DB, Budhathoki P, Sedhai YR, Baniya R, Cable CA, Kashiouris MG, et al. Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis. Current Therapeutic Research. 2021; 95: 100635.","DOI":"10.1016\/j.curtheres.2021.100635"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Anker SD, Kosiborod M, Zannad F, Pi\u00f1a IL, McCullough PA, Filippatos G, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. European Journal of Heart Failure. 2015; 17: 1050\u20131056.","DOI":"10.1002\/ejhf.300"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Pi\u00f1a IL, Yuan J, Ackourey G, Ventura H. Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials. Progress in Cardiovascular Diseases. 2020; 63: 656\u2013661.","DOI":"10.1016\/j.pcad.2020.09.007"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Roger S, Spinowitz B, Lerma E, Singh B, Packham D, Al-Shurbaji A, et al. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: an 11-Month Open-Label Extension of HARMONIZE. American Journal of Nephrology. 2019; 50: 473\u2013480.","DOI":"10.1159\/000504078"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Kosiborod M, Peacock WF, Packham DK. Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia. The New England Journal of Medicine. 2015; 372: 1577\u20131578.","DOI":"10.1056\/NEJMc1500353"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine. 2021; 385: 1451\u20131461.","DOI":"10.1056\/NEJMoa2107038"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F, et al. Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2020; 383: 1436\u20131446.","DOI":"10.1056\/NEJMoa2024816"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet. 2020; 396: 819\u2013829.","DOI":"10.1016\/S0140-6736(20)31824-9"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients with Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation. 2021; 143: 337\u2013349.","DOI":"10.1161\/CIRCULATIONAHA.120.051824"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2019; 381: 1995\u20132008.","DOI":"10.1056\/NEJMoa1911303"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42: 3599\u20133726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Maddox TM, Januzzi JL, Allen LA, Breathett K, Butler J, Davis LL, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues about Heart Failure with Reduced Ejection Fraction. Journal of the American College of Cardiology. 2021; 77: 772\u2013810.","DOI":"10.1016\/j.jacc.2020.11.022"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Wheeler DC, Stef\u00e1nsson BV, Jongs N, Postmus D, Correa-Rotter R, et al. Effect of Dapagliflozin on Clinical ssOutcomes in Patients with Chronic Kidney Disease, with and without Cardiovascular Disease. Circulation. 2021; 143: 438\u2013448.","DOI":"10.1161\/CIRCULATIONAHA.120.051675"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine. 2017; 377: 2099.","DOI":"10.1056\/NEJMc1712572"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Wanner C, Inzucchi SE, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. The New England Journal of Medicine. 2016; 375: 1801\u20131802.","DOI":"10.1056\/NEJMc1611290"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Packer M, Zannad F, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. European Journal of Heart Failure. 2021; 23: 1798\u20131799.","DOI":"10.1002\/ejhf.2334"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European Journal of Heart Failure. 2021; 23: 1217\u20131225.","DOI":"10.1002\/ejhf.2249"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Fu M, Zhou J, Thunstr\u00f6m E, Almgren T, Grote L, Bollano E, et al. Optimizing the Management of Heart Failure with Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF) Journal of Cardiac Failure. 2016; 22: 539\u2013544.","DOI":"10.1016\/j.cardfail.2016.01.011"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"van de Wouw J, Broekhuizen M, Sorop O, Joles JA, Verhaar MC, Duncker DJ, et al. Chronic Kidney Disease as a Risk Factor for Heart Failure with Preserved Ejection Fraction: a Focus on Microcirculatory Factors and Therapeutic Targets. Frontiers in Physiology. 2019; 10: 1108.","DOI":"10.3389\/fphys.2019.01108"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron. Clinical Practice. 2012; 120: c179\u2013c184.","DOI":"10.1159\/000339789"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Doshi R, Dhawan T, Rendon C, Rodriguez MA, Al-khafaji JF, Taha M, et al. Incidence and implications of acute kidney injury in patients hospitalized with acute decompensated heart failure. Internal and Emergency Medicine. 2020; 15: 421\u2013428.","DOI":"10.1007\/s11739-019-02188-z"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Obokata M, Testani JM, Felker GM, Tang WHW, Abou-Ezzeddine OF, et al. Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure. 2020; 26: 101\u2013107.","DOI":"10.1016\/j.cardfail.2019.09.015"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, et al. Worsening Renal Function in Patients with Acute Heart Failure Undergoing Aggressive Diuresis is not Associated with Tubular Injury. Circulation. 2018; 137: 2016\u20132028.","DOI":"10.1161\/CIRCULATIONAHA.117.030112"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney International. 2012; 81: 442\u2013448.","DOI":"10.1038\/ki.2011.379"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Forman DE, Butler J, Wang Y, Abraham WT, O\u2019Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. Journal of the American College of Cardiology. 2004; 43: 61\u201367.","DOI":"10.1016\/j.jacc.2003.07.031"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Bei WJ, Wang K, Li HL, Lin KY, Guo XS, Chen SQ, et al. Safe Hydration Volume to Prevent Contrast-induced Acute Kidney Injury and Worsening Heart Failure in Patients With Heart Failure and Preserved Ejection Fraction After Cardiac Catheterization. Journal of Cardiovascular Pharmacology. 2017; 70: 168\u2013175.","DOI":"10.1097\/FJC.0000000000000502"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/23\/2\/10.31083\/j.rcm2302069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:36:18Z","timestamp":1732728978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/23\/2\/10.31083\/j.rcm2302069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"alternative-id":["S1530-6550(22)00356-8"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2302069","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"article-number":"69"}}